Patients w/ bleeding diatheses, thrombocytopenia, taking anticoagulants, or critical visceral disease. Thromboembolic events in women w/ advanced breast cancer. Caution while administering at the dorsogluteal inj site. Potential risk of osteoporosis. May interfere w/ Ab based-estradiol assays. Caution in patients experiencing asthenia when driving or operating machinery. Mild to moderate hepatic impairment, severe renal impairment (CrCl <30 mL/min). Women of childbearing potential should use effective contraception during treatment. Childn & adolescents.